编号：2015-002 号 证券代码：002742 证券简称：三圣特材 重庆三圣特种建材股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|----------------------|----------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | | □媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | 1 | 、中银国际证券有限责任公司：王钦 | | | 2 | 、国联安基金管理有限公司：顾益辉 | | | 3 | 、广发证券股份有限公司：谢璐 | | 参与单位名称及 | 4 | 、国泰君安证券资产管理公司：祝捷 | | 人员姓名 | 5 | 、安诚财产保险股份有限公司：卢敬之 | | | 6 | 、国信证券经济研究所、重庆分公司：黄道立、周 | | | 忻、宋占宇、刘宏 | | | 时间 | 2015 年 11 月 | ...

编号：2016-001 号 证券代码：002742 证券简称：三圣特材 重庆三圣特种建材股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------|--------------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | | □媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | 1 | 、重庆产业引导股权投资基金有限责任公司邹一沙 | | 参与单位名称及 | 2 | 、昆吾九鼎投资管理有限公司西南分公司石全胜 | | 人员姓名 | 3 | 、和信融智资产管理有限公司黄前松、蒋德军 | | 时间 | 2016 年 7 月 14 | 日下午 2 点 | | 地点 | 公司 1212 会议室 | | | 上市公司接待人 员姓名 | 董秘张凯、证代丁仁均 | | | 投资者关系活动 | 交流内 ...

编号：2017-001 号 证券代码：002742 证券简称：三圣股份 重庆三圣实业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|------------------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | 1 | 、广发证券发展研究中心 谢璐 | | | 2 | 、银河基金研究部 王翊 | | 参与单位名称及 | 3 | 、招商证券研究发展中心 郑晓刚、李点典 | | 人员姓名 | 4 | 、东吴证券研究所 焦德智 | | | 5 | 、国海富兰克林基金研究分析部 赵宇烨 | | 时间 | 2017 年 5 月 22 | 日 | | 地点 | 公司 1212 会议室 | | | 上市公司接待人 | | 董事长潘先文、董事 ...

证券代码：002742 证券简称：三圣股份 重庆三圣实业股份有限公司 投资者关系活动记录表 编号：2018-001 号 | --- | --- | --- | |----------------|---------------------------------|--------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | | □新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ 其他） | | | | 1 | 、国泰君安证券股份有限公司：鲍雁辛、黄涛； | | 参与单位名称及 | 2 | 、深圳市基石资产管理股份有限公司 柴妍； | | | | | | 人员姓名 | 3 | 、弢盛资产 张云鹏； | | | 4 | 、。重庆诺鼎资产管理有限公司 曾宪钊。 | | 时间 | 2018 年 1 月 22 | 日 14:00-17:00 | | 地点 | 公司 | | | 上市公司接待人 | 董事长：潘先文 董事会秘书：张凯 | | | 员姓名 | ...

证券代码：002742 证券简称：三圣股份 重庆三圣实业股份有限公司 投资者关系活动记录表 编号：2017-002 号 | --- | --- | --- | |----------------|-------------------------------------|------------------------------------------------------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | 其他（深交所联合重庆证监局在公司举办"践行中国梦•走 | | | 近上市公司"投资者开放日活动） | | | | 1 | 、通过西南证券、红塔证券、上海证券、华福证券、 湘财证券、南京证券、广发证券、德同资本等报名的近 40 | | | | | | 人员姓名 | | 2、证券时报、证券日报、全景财经、第一财经等 8 | | 参 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥962,826,665.42, a decrease of 21.10% compared to ¥1,220,255,739.91 in the same period last year[24]. - The net loss attributable to shareholders was ¥40,738,537.48, representing a decline of 154.51% from a loss of ¥16,006,931.98 in the previous year[24]. - The net profit after deducting non-recurring gains and losses was ¥-35,750,132.27, which is a 21.11% increase in loss compared to ¥-29,517,672.30 last year[24]. - The basic earnings per share were ¥-0.0943, down 154.18% from ¥-0.0371 in the same period last year[24]. - The company reported a significant increase in investment, with ¥81,061,612.29 in the reporting period, a change of 2,528.22% compared to the previous year[56]. - The company reported a total comprehensive loss of CNY 27,882,149.96 for the first half of 2022, compared to a loss of CNY 76,542,891.78 in the same period of 2021[163]. - The net profit for the first half of 2022 was a loss of CNY 27,882,149.96, compared to a loss of CNY 76,542,891.78 in the same period of 2021, indicating a narrowing of losses[163]. - The company reported a net loss of 24.1161 million yuan for 2022, indicating significant financial challenges[184]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,111,061,163.44, a decrease of 6.84% from ¥4,413,070,944.02 at the end of the previous year[24]. - The net assets attributable to shareholders decreased by 3.54% to ¥1,081,189,903.37 from ¥1,120,844,682.25 at the end of the previous year[24]. - The total liabilities decreased to ¥2,848,680,833.70 from ¥3,099,798,674.40 at the beginning of the year[151]. - The company reported a total debt of 65,000 million as of June 20, 2022, with a significant portion maturing on December 1, 2022[116]. - The company has a total approved guarantee amount of CNY 546.5 million during the reporting period, with actual guarantees amounting to CNY 41.8 million[119]. Cash Flow - The net cash flow from operating activities was ¥60,959,395.02, a slight decrease of 2.48% compared to ¥62,508,850.13 in the same period last year[24]. - The cash and cash equivalents net increase was ¥28.51 million, a decline of 64.69% compared to the previous year[46]. - The ending balance of cash and cash equivalents was ¥77,821,997.33, down 50.5% from ¥156,873,058.89 at the end of the first half of 2021[165]. - Total cash inflow from operating activities decreased to ¥843,293,629.32, down 31.7% from ¥1,235,645,619.69 in the first half of 2021[164]. - Cash outflow from operating activities also decreased to ¥782,334,234.30, a reduction of 33.3% compared to ¥1,173,136,769.56 in the previous year[164]. Business Segments - The company operates in two main business segments: construction materials and pharmaceuticals, with a leading position in ready-mixed concrete and additives in the construction materials sector[32]. - The pharmaceutical segment includes intermediates and active pharmaceutical ingredients, with key products such as procaine hydrochloride and cephalosporin intermediates, which hold a leading market position[33]. - The construction materials segment's revenue is primarily derived from ready-mixed concrete, concentrated in the Chongqing region, benefiting from the city's strategic economic position[35]. - The pharmaceutical manufacturing segment achieved profitability, contributing positively to the company's overall performance through enhanced management and market expansion efforts[38]. Market Conditions and Strategies - The company reported a loss in its main business due to severe market shocks in the construction materials sector, exacerbated by cash flow issues and strict environmental policies[37]. - The construction materials industry is closely tied to macroeconomic conditions, with demand expected to remain high due to ongoing infrastructure investments in Chongqing[36]. - The company has implemented various measures to mitigate losses, including internal management improvements and product price adjustments[38]. - The company plans to enhance its market expansion and diversification strategies to mitigate regional sales concentration risks[66]. - The company aims to improve its profitability by optimizing inventory management and enhancing accounts receivable turnover[68]. Environmental Compliance - The company strictly complies with various environmental protection laws and standards, including the Air Pollution Prevention and Control Law and the Water Pollution Prevention and Control Law[77]. - The wastewater treatment plant operates within the limits of chemical oxygen demand (COD) at less than 100 mg/L and ammonia nitrogen at less than 15 mg/L[79]. - The company has implemented measures to ensure that emissions of particulate matter are below 30 mg/m3 and sulfuric acid mist below 5 mg/m3[79]. - The company has not reported any instances of exceeding pollution discharge standards[79]. Corporate Governance and Investor Relations - The company adheres to regulations for shareholder meetings, ensuring the rights of minority shareholders are protected through both in-person and online voting options[87]. - The company has established an investor hotline to enhance communication with minority investors, providing timely updates on company developments[87]. - The board secretary is responsible for information disclosure, ensuring compliance with regulatory standards and maintaining transparency with investors[87]. - The company has committed to fulfilling its promises regarding the initial public offering, with ongoing compliance monitored[89]. Future Outlook - The company plans to expand its market presence and invest in new product development in the upcoming quarters[170]. - The company aims to achieve a revenue growth target of 10% for the next fiscal year, driven by new product launches and market expansion efforts[170]. - Future guidance indicates a projected revenue growth of 10% for the next half-year, driven by increased demand and market expansion efforts[174].

Financial Performance - The company's operating revenue for Q1 2022 was ¥453,744,979.80, a decrease of 18.46% compared to ¥556,440,760.58 in the same period last year[3]. - The net profit attributable to shareholders was ¥5,242,468.17, down 79.39% from ¥25,432,495.73 year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,353,261.68, a decline of 94.58% compared to ¥24,957,499.98 in the previous year[3]. - Net profit for the current period was ¥11,543,202.81, a decline of 64.1% from ¥32,202,374.09 in the previous period[17]. - The total comprehensive income attributable to the parent company was -3,585,025.85 CNY, compared to 14,703,286.67 CNY in the previous period, indicating a significant decline[18]. - The basic and diluted earnings per share were both 0.0121 CNY, a decrease from 0.0589 CNY in the previous period[18]. Cash Flow - The net cash flow from operating activities was -¥22,050,335.26, a significant decrease of 211.90% from ¥19,705,673.55 in the same period last year[3]. - Cash received from the sale of goods and services was 288,579,411.32 CNY, down from 507,096,538.96 CNY in the previous period[20]. - The total cash outflow from operating activities was 429,841,376.98 CNY, down from 640,131,996.11 CNY in the previous period[21]. - The net cash flow from investing activities was -17,120,899.80 CNY, compared to -13,247,263.42 CNY in the previous period, reflecting increased investment outflows[21]. - The net cash flow from financing activities was 26,727,923.35 CNY, compared to -32,900,038.64 CNY in the previous period, indicating a recovery in financing[22]. - The total cash inflow from financing activities was 199,100,000.00 CNY, an increase from 124,700,000.00 CNY in the previous period[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,238,393,725.92, down 3.96% from ¥4,413,070,944.02 at the end of the previous year[3]. - Current assets totaled ¥1,850,317,112.41, down 9.5% from ¥2,044,517,296.79 at the beginning of the year[12]. - The company's total assets decreased to ¥4,238,393,725.92 from ¥4,413,070,944.02, representing a reduction of 3.95%[14]. - The total liabilities decreased to ¥2,935,849,222.17 from ¥3,099,798,674.40, a decline of 5.3%[14]. - The company's long-term borrowings decreased to ¥196,208,333.13 from ¥268,000,000.00, a reduction of 26.8%[14]. Operational Metrics - The company reported a significant reduction in cash and cash equivalents, with a decrease of 45.81% in monetary funds to ¥97,547,210.36[6]. - The company experienced an 85.38% decrease in receivables financing, totaling ¥6,244,326.62, primarily due to cash payments to suppliers[6]. - Total operating costs amounted to ¥457,827,141.40, down from ¥533,455,565.37, reflecting a reduction of 14.1%[16]. - Research and development expenses were ¥4,898,797.18, down 28.7% from ¥6,875,272.23 in the previous period[17]. - Accounts receivable decreased to ¥1,132,709,492.32 from ¥1,182,940,925.41, a reduction of 4.2%[12].

Financial Performance - The company reported a significant increase in revenue, with a total of 1.2 billion RMB for the year, representing a growth of 15% compared to the previous year[1]. - The company's operating revenue for 2021 was ¥2,489,145,222.21, a decrease of 2.37% compared to ¥2,549,509,857.65 in 2020[21]. - The net profit attributable to shareholders for 2021 was -¥333,437,976.48, representing a decline of 554.05% from a profit of ¥73,436,772.60 in 2020[21]. - The company's total revenue for 2021 was ¥2,489,145,222.21, a decrease of 2.37% compared to ¥2,549,509,857.65 in 2020[54]. - The construction materials segment generated revenue of ¥1,583,309,655.22, down 14.38% from ¥1,849,300,071.48 in the previous year, accounting for 63.61% of total revenue[55]. - The pharmaceutical segment achieved revenue of ¥867,146,237.43, an increase of 30.41% from ¥664,916,596.01 in 2020, representing 34.84% of total revenue[55]. - The company reported a significant increase in financial pressure due to tightening liquidity and rising financing costs, impacting overall profitability[50]. Market and Growth Strategies - The company has outlined a future outlook with a projected revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[1]. - The company is positioned as a major player in the global chemical raw material and pharmaceutical formulation production markets, with China accounting for 20% of the global pharmaceutical sales market[39]. - The company has implemented an internationalization strategy, with overseas projects beginning to yield results[41]. - The company is actively pursuing international expansion, particularly in Africa, to diversify its market presence and reduce business risks[89]. Research and Development - Investment in new product development increased by 25%, focusing on innovative materials and technologies in the construction sector[1]. - The company has invested in R&D, establishing a pharmaceutical research center that supports new drug development and has a complete drug R&D system[44]. - The company filed 11 patent applications and participated in the formulation of 8 national industry standards during the reporting period, enhancing its innovation capabilities[51]. - The company aims to strengthen its research and development capabilities, particularly in extending product life cycles and promoting original research[88]. Corporate Governance and Internal Controls - Internal control deficiencies were identified, with the actual controller having significant influence over the company's operations, which may pose risks[1]. - The company has committed to enhancing its corporate governance practices to address identified risks and improve transparency[1]. - The company reported a significant internal control deficiency related to the misuse of funds by major shareholders, with corrective measures planned for implementation by April 18, 2022[128]. - The company plans to strengthen internal control management and improve the internal audit department's functions to prevent future issues[129]. - The company has implemented measures to prevent non-operating fund occupation by major shareholders and related parties, including strengthening management systems and internal controls[135]. Environmental and Social Responsibility - The company has initiated comprehensive environmental remediation efforts, including the installation of dust reduction and solid waste disposal equipment, to ensure sustainable operations[51]. - The company has established a self-monitoring plan in compliance with environmental regulations[146]. - The company conducts at least one emergency drill for environmental incidents annually[147]. - The company has implemented a waste classification system, with wastewater categorized into five types for proper treatment[144]. - The company has not conducted any poverty alleviation or rural revitalization work during the reporting period[152]. Legal and Compliance Issues - The accounting firm Tianjian has issued a non-standard audit report, highlighting significant uncertainties related to the company's ongoing operations[162]. - The company has not reported any environmental accidents during the reporting period[149]. - The company is involved in ongoing litigation with amounts exceeding 1 billion, indicating potential future cash inflows[170]. - The company has successfully resolved disputes with several construction firms, resulting in favorable outcomes and payments received[169]. Leadership and Management Changes - The company experienced changes in its board of directors, with multiple resignations including the chairman and general manager on August 25, 2021[101]. - The company appointed Xiang Liping as the chairman and general manager on November 26, 2021[102]. - The company has been actively adjusting its management team to enhance operational efficiency[101]. - The management team includes professionals with backgrounds in finance, engineering, and pharmaceuticals, indicating a diverse skill set[105][106]. Employee and Shareholder Engagement - The company has established a performance-oriented compensation system to motivate employees, which includes base salary, performance bonuses, and incentives[123]. - The company ensures shareholder rights by providing both in-person and online voting options for shareholders[150]. - The company maintains investor relations through regular disclosures and a dedicated investor hotline[151]. - The total remuneration for directors, supervisors, and senior management in 2021 amounted to 358.88 million CNY[114].

证券代码：002742 证券简称：三圣股份 公告编号：2021-82 号 重庆三圣实业股份有限公司 关于参加重庆辖区上市公司 2021 年投资者网上集体 接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为推动辖区上市公司做好投资者关系管理工作，促进上市公司完善公司治 理，进一步提高上市公司质量，在重庆证监局指导下，重庆上市公司协会联合上 证所信息网络有限公司、深圳市全景网络有限公司举办辖区上市公司2021年投资 者网上集体接待日活动。 活动将于2021年11月25日（星期四）15:00-17:00举行，投资者可以通过"全 景·路演天下"（http://rs.p5w.net）进入本公司互动平台参与互动交流。 届时，公司相关高管人员将参加本次活动，通过网络在线交流形式，就投资 者所关心的问题，与投资者进行"一对多"形式的在线沟通与交流。欢迎广大投 资者踊跃参与！ 特此公告。 重庆三圣实业股份有限公司董事会 2021 年 11 月 19 日 ...

Financial Performance - The company's revenue for Q3 2021 was ¥569,396,259.96, a decrease of 19.67% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥26,937,583.85, representing a significant decline of 1,365.06% year-on-year[3]. - The basic earnings per share were -¥0.0623, reflecting a decline of 1,346.17% compared to the same period last year[3]. - Total operating revenue for Q3 2021 was CNY 1,789,651,999.87, a decrease of 2.7% compared to CNY 1,839,114,496.46 in the same period last year[22]. - Net profit for Q3 2021 was a loss of CNY 20,787,859.47, compared to a profit of CNY 67,775,680.76 in Q3 2020, marking a significant decline[23]. - The company reported a basic and diluted earnings per share of -0.0994, a decline from 0.1107 in the same quarter last year[24]. - Other comprehensive income after tax was a loss of CNY 57,255,975.16, compared to a loss of CNY 69,867,194.08 in the previous year[23]. Cash Flow and Assets - The net cash flow from operating activities was -¥25,165,735.87, down 66.62% year-to-date[3]. - The cash flow from operating activities was CNY 1,481,304,876.44, compared to CNY 1,674,913,996.86 in the previous period[26]. - The net cash flow from operating activities for Q3 2021 was -25,165,735.87 CNY, an improvement from -75,391,345.76 CNY in Q3 2020[27]. - Total assets at the end of the reporting period were ¥4,318,229,013.65, a decrease of 11.47% from the previous year[4]. - The company's total assets decreased to CNY 4,318,229,013.65 from CNY 4,877,608,615.06, reflecting a reduction of approximately 11.5%[20]. - The ending balance of cash and cash equivalents was 32,937,767.53 CNY, a decrease from 93,973,708.20 CNY at the end of Q3 2020[28]. - The company experienced a 32.82% decrease in cash and cash equivalents, totaling ¥232,230,745.89, primarily due to concentrated payments during the Spring Festival[8]. - As of September 30, 2021, the company's cash and cash equivalents decreased to ¥232,230,745.89 from ¥345,678,809.61 at the end of 2020, representing a decline of approximately 32.7%[18]. Liabilities and Equity - Total liabilities decreased to CNY 2,649,485,900.54, down from CNY 3,121,460,928.61, indicating a reduction of about 15.1%[20]. - The total equity attributable to shareholders decreased by 5.48% to ¥1,432,837,177.18[4]. - The company has pledged 100% of its equity in Liaoyuan Baikang Pharmaceutical Co., Ltd. for loans totaling ¥66,961,511.27, with the last loan due on November 22, 2021[15]. - The company has also pledged 72% of its equity in Chongqing Chunrui Pharmaceutical Chemical Co., Ltd. for loans totaling ¥409,000,000.00, with the last loan due on May 20, 2023[15]. - The first major shareholder, Mr. Pan Xianwen, has pledged 165,934,132 shares, which is 97.69% of his holdings, and 35,036,472 shares are frozen, accounting for 20.63% of his total shares[14]. - The actual controller and his associates have cumulatively reduced their holdings by 78,197,572 shares, which is 18.10% of the total share capital[14]. Operational Changes and Future Outlook - The company expects to obtain the gypsum mining license and resume mining operations by the end of 2021, following the approval from the Chongqing Municipal Government[13]. - The company is actively communicating with government departments to restore its gypsum mining rights, which have been suspended since July 2018 due to regulatory restrictions[12]. - The company has undergone changes in its board of directors and supervisory board, with several resignations and new appointments made in September 2021[14]. Expenses - The company reported a significant increase in sales expenses, which rose by 54.95% to ¥18,894,744.14, aimed at maintaining sales volume[8]. - Total operating costs increased to CNY 1,842,094,776.80, up 4.2% from CNY 1,768,551,127.11 year-on-year[22]. - Research and development expenses for the quarter were CNY 20,996,221.29, slightly down from CNY 21,867,690.38 year-on-year[22]. Investment Activities - Cash inflow from investment activities was 239,940,174.00 CNY, significantly higher than 15,401,820.00 CNY in the same period last year[27]. - The net cash flow from investment activities was 77,789,019.63 CNY, compared to -64,306,350.45 CNY in Q3 2020[27].